News
Femtech founders win bursary for AI-powered menstrual app
Female-founded app, Hormonious Flo, has been awarded a £5,000 bursary, as part of Starling Bank’s Take Flight campaign for small businesses.
Alexis Abayomi, a self-taught app developer, teamed up with menstrual-health coach and psychology student Sasha Cayward to develop an app that helps women to track their menstrual cycle symptoms like period pain or acne and eliminate them through a holistic wellness approach.
The femtech startup is on a mission to arm the 90 per cent of women that experience hormonal imbalances with the knowledge, tools, and guidance required to have symptom-free periods.
Unlike previously-developed period trackers, this app offers personalised content on nutrition, fitness, lifestyle and mindset, both co-founders stressing the importance of working with one’s own body and life instead of having a “one size fits all approach” that permeates the wellness industry.
Entrepreneur and TV personality Carol Vorderman was joined by other founders on the judging panel in naming Hormonious Flo a winner, after Alexis and Sasha impressed them all with the app’s ambitious growth model.
With the aim to widen its network of doctors, personal trainers, hormone specialists and nutritionists, the two founders hope to become the number one NHS-recommended app for menstrual health-related symptoms.
“The female body has long been mis-understood, but the femtech revolution has empowered women with invaluable tools,” says Abayomi.
“When we started out in femtech, we realised that most apps out there focus on fertility and period tracking. There was a gap in the market for an app that helps women feel good in their bodies every day,” she adds.
“Women and menstruators were tracking their symptoms, but there was nothing to help them alleviate these problems they were having. I built the first iteration of Hormonious Flo in 2020, which was a big success and with the bursary from Starling, we’ll hire the developer and marketing talent so that we can bring the app to the masses.”
The prize money was one of ten offered by Starling to celebrate its Take Flight Initiative – a support package for UK small businesses. In addition to the £50,000 total fund, Starling’s team of expert entrepreneurs assembled to offer small businesses the advice they wished they’d known when starting out.
Carol Vorderman, pilot and founder of The Maths Factor says that: “What struck me most when judging this competition is how much creativity, tenacity and drive exists within Starling Bank’s business customers. Every entry was brilliant in its own way, but our ten winners impressed us with their unique business models, ambitious growth plans, and sense of purpose.
“I wish them all the best for 2022 and beyond and I hope the Take Flight bursary helps them to reach new heights this year.”
The app is available is App Store and Google Play.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Fertility
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Wellness2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Entrepreneur4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







2 Comments